Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, baricitinib was well tolerated and led to clinical improvement in patients with treatment-resistant alopecia areata in a real-world clinical setting, suggesting it may be a potential treatment option.

Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This case report highlights significant improvement in a patient with severe alopecia areata who responded well to ivarmacitinib after a suboptimal response to another JAK inhibitor, tofacitinib, suggesting ivarmacitinib as a potential alternative for tofacitinib-refractory cases.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

This review discusses hypersensitivity reactions to anticoagulants like ASA and heparins, highlighting their rare but potentially life-threatening nature, and emphasizes the need for meticulous allergy testing to find safe alternatives.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

This review discusses baricitinib's applications for various inflammatory disorders and highlights its promising efficacy alongside potential adverse effects, advocating for further research before it becomes a standard treatment.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

This study highlights the recent FDA approval of baricitinib as the first on-label treatment for severe alopecia areata, whereas previous treatments were off-label therapies like systemic steroids and immunosuppressants.

In a Belgian cohort study, nearly 90% of alopecia areata patients treated with oral baricitinib experienced hair regrowth, with more than 70% achieving a favorable SALT score, particularly in patchy cases, though some relapsed post-treatment. No serious adverse events were noted.

This study found that oral Janus kinase inhibitors were effective in treating alopecia areata, with a clinical response rate of 48.3%, though further research is needed to assess long-term effects.

Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

In this study, reversible ageusia in a patient was strongly suggested to be caused by losartan, with potential implications for angiotensin receptor involvement in taste disturbance.

In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.

This retrospective study observed that patients with vascular EDS on long-term angiotensin II receptor blockers or beta-blockers experienced fewer vascular events compared to those without cardiac medication under similar lifestyle and emergency care advice.

In this six-year study of a Saudi cohort, oral tofacitinib showed favorable long-term effectiveness for patients with AA, with manageable adverse events requiring regular monitoring.

This case report details a 72-year-old man who experienced a lichenoid eruption and alopecia linked to captopril, which resolved after stopping the drug, suggesting a possible immunological mechanism.

In this study, baricitinib improved the resolution of arthritis or rash in patients with systemic lupus erythematosus, but outcomes for skin involvement like alopecia were not reported.

This study observed that although 5-alpha-reductase inhibitors reduce PSA density in patients on active surveillance for prostate cancer, those who progress to more serious disease still show higher PSA densities, suggesting these inhibitors accentuate differences in clinically significant cases.

In an outpatient cardiology center, this study found that introducing the AHA/ACC ABI screening protocol significantly increased the frequency of ABI ordering by 31.6% for symptomatic patients.

A medicine company has recalled a drug because it contained an unlisted blood pressure medication.

This study found that both ruxolitinib and tofacitinib were effective in promoting hair regrowth for patients with severe alopecia areata, with no significant difference in efficacy and relapse rate between them, and both were well tolerated throughout the treatment.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

This review suggests that oral Janus kinase inhibitors like tofacitinib, ruxolitinib, and baricitinib show promise for treating alopecia areata in adults, both in terms of efficacy and safety.

In this study, adults with severe alopecia areata experienced greater improvements in hair regrowth, health-related quality of life, and reduced anxiety and depression symptoms after 36 weeks of treatment with baricitinib compared to placebo.

In this case study, a patient with refractory oral lichen planus experienced marked improvement within one month of daily treatment with baricitinib, contributing to the evidence supporting the use of JAK inhibitors for lichen planus.

This case report highlights the successful treatment of alopecia areata universalis with Baricitinib, suggesting potential long-term effectiveness of janus kinase inhibitors for this autoimmune hair loss condition.